MX2015013380A - Inmunoterapia para cordoma a base de levadura. - Google Patents
Inmunoterapia para cordoma a base de levadura.Info
- Publication number
- MX2015013380A MX2015013380A MX2015013380A MX2015013380A MX2015013380A MX 2015013380 A MX2015013380 A MX 2015013380A MX 2015013380 A MX2015013380 A MX 2015013380A MX 2015013380 A MX2015013380 A MX 2015013380A MX 2015013380 A MX2015013380 A MX 2015013380A
- Authority
- MX
- Mexico
- Prior art keywords
- chordoma
- yeast
- based immunotherapy
- individual
- relates
- Prior art date
Links
- 201000009047 Chordoma Diseases 0.000 title abstract 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Abstract
Una modalidad de la invención se refiere a un método para tratar cordoma en un individuo que tiene cordoma. El método incluye el paso de administrar a un individuo que tiene cordoma, una composición inmunoterapéutica que comprende: (a); y (b) un antígeno cancerígeno que comprende al menos un antígeno de Braquiuria. Otra modalidad de la invención se refiere al uso de una composición inmunoterapéutica que comprende un vehículo de levadura que comprende al menos un antígeno de Braquiuria para cordoma en un individuo que tiene cordoma. Aún otra modalidad de la invención se refiere al uso de una composición inmunoterapéutica que comprende un vehículo de levadura.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361803332P | 2013-03-19 | 2013-03-19 | |
| PCT/US2014/031183 WO2014186047A1 (en) | 2013-03-19 | 2014-03-19 | Yeast-based immunotherapy for chordoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015013380A true MX2015013380A (es) | 2016-01-08 |
Family
ID=51898771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013380A MX2015013380A (es) | 2013-03-19 | 2014-03-19 | Inmunoterapia para cordoma a base de levadura. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10507235B2 (es) |
| EP (1) | EP2976100B1 (es) |
| JP (1) | JP6509808B2 (es) |
| KR (1) | KR20150132867A (es) |
| CN (1) | CN105228646B (es) |
| AU (1) | AU2014265873B2 (es) |
| BR (1) | BR112015023968A2 (es) |
| CA (1) | CA2907560C (es) |
| HK (1) | HK1216861A1 (es) |
| IL (1) | IL241384B (es) |
| MX (1) | MX2015013380A (es) |
| RU (1) | RU2679806C2 (es) |
| SG (2) | SG11201507328RA (es) |
| TW (2) | TWI674108B (es) |
| WO (1) | WO2014186047A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3051449A1 (de) * | 2015-01-29 | 2016-08-03 | Bayer Technology Services GmbH | Computerimplementiertes Verfahren zur Erstellung eines Fermentationsmodels |
| TWI748957B (zh) * | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 |
| EP4137150A1 (en) | 2015-08-03 | 2023-02-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
| US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
| IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
| US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US7175839B1 (en) | 1997-10-10 | 2007-02-13 | Meyer Pharmaceuticals Llc | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| US8153414B2 (en) | 2000-04-06 | 2012-04-10 | Allertein Therapeutics, Llc | Microbial delivery system |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| CN1938044B (zh) | 2002-12-16 | 2011-12-28 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| US20060009404A1 (en) | 2004-07-09 | 2006-01-12 | Williams Jason R | Tumor ablation in combination with pharmaceutical compositions |
| WO2007008780A2 (en) | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| IN2014DN08830A (es) | 2006-02-02 | 2015-07-10 | Globeimmune Inc | |
| EP2004666B1 (en) | 2006-03-27 | 2014-09-03 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
| SG10201405420QA (en) | 2007-02-02 | 2014-10-30 | Globeimmune Inc | Methods for producing yeast-based vaccines |
| EP2918598B1 (en) * | 2007-02-28 | 2019-01-30 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
| WO2008115610A1 (en) | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
| JP2013522302A (ja) | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| WO2012083302A2 (en) | 2010-12-17 | 2012-06-21 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| JP5745102B2 (ja) | 2011-02-12 | 2015-07-08 | グローブイミューン，インコーポレイテッド | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 |
| BR112013023456B1 (pt) | 2011-03-17 | 2020-11-17 | Globeimmune, Inc. | composições imunoterapêuticas de levedura brachyury, e seus usos |
| EA030381B1 (ru) | 2011-06-14 | 2018-07-31 | Глоубиммьюн, Инк. | Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта |
| AU2012296425B2 (en) | 2011-08-17 | 2017-07-20 | Globeimmune, Inc. | Yeast-MUC1 immunotherapeutic compositions and uses thereof |
| TWI748957B (zh) | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 |
-
2014
- 2014-03-19 AU AU2014265873A patent/AU2014265873B2/en active Active
- 2014-03-19 TW TW103110360A patent/TWI674108B/zh active
- 2014-03-19 SG SG11201507328RA patent/SG11201507328RA/en unknown
- 2014-03-19 WO PCT/US2014/031183 patent/WO2014186047A1/en active Application Filing
- 2014-03-19 MX MX2015013380A patent/MX2015013380A/es active IP Right Grant
- 2014-03-19 SG SG10201707608QA patent/SG10201707608QA/en unknown
- 2014-03-19 EP EP14797995.9A patent/EP2976100B1/en active Active
- 2014-03-19 JP JP2016504343A patent/JP6509808B2/ja active Active
- 2014-03-19 KR KR1020157030048A patent/KR20150132867A/ko not_active IP Right Cessation
- 2014-03-19 US US14/778,118 patent/US10507235B2/en active Active
- 2014-03-19 CN CN201480028312.1A patent/CN105228646B/zh active Active
- 2014-03-19 CA CA2907560A patent/CA2907560C/en active Active
- 2014-03-19 TW TW108107386A patent/TW201936206A/zh unknown
- 2014-03-19 BR BR112015023968A patent/BR112015023968A2/pt not_active Application Discontinuation
- 2014-03-19 RU RU2015144511A patent/RU2679806C2/ru active
-
2015
- 2015-09-09 IL IL241384A patent/IL241384B/en active IP Right Grant
-
2016
- 2016-04-29 HK HK16104939.8A patent/HK1216861A1/zh unknown
-
2019
- 2019-10-25 US US16/664,543 patent/US20200046818A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2976100A4 (en) | 2016-10-19 |
| SG10201707608QA (en) | 2017-10-30 |
| JP2016516081A (ja) | 2016-06-02 |
| WO2014186047A1 (en) | 2014-11-20 |
| AU2014265873B2 (en) | 2019-01-17 |
| TWI674108B (zh) | 2019-10-11 |
| SG11201507328RA (en) | 2015-10-29 |
| CA2907560C (en) | 2021-12-07 |
| EP2976100B1 (en) | 2020-07-01 |
| JP6509808B2 (ja) | 2019-05-08 |
| CN105228646A (zh) | 2016-01-06 |
| BR112015023968A2 (pt) | 2017-08-22 |
| TW201446261A (zh) | 2014-12-16 |
| TW201936206A (zh) | 2019-09-16 |
| HK1216861A1 (zh) | 2016-12-09 |
| EP2976100A1 (en) | 2016-01-27 |
| US20160271238A1 (en) | 2016-09-22 |
| CA2907560A1 (en) | 2014-11-20 |
| RU2679806C2 (ru) | 2019-02-13 |
| IL241384B (en) | 2019-12-31 |
| KR20150132867A (ko) | 2015-11-26 |
| RU2015144511A (ru) | 2017-05-03 |
| CN105228646B (zh) | 2021-04-06 |
| IL241384A0 (en) | 2015-11-30 |
| AU2014265873A1 (en) | 2015-10-22 |
| US20200046818A1 (en) | 2020-02-13 |
| WO2014186047A8 (en) | 2015-01-15 |
| US10507235B2 (en) | 2019-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| PH12015500196B1 (en) | Methods of treating a tauopathy | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| MX2022010623A (es) | Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer. | |
| PH12016501763A1 (en) | Multispecific antibodies | |
| MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| MX2019015604A (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia. | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| MX2013010475A (es) | Composiciones inmunoterapeuticas de levadura-brachyuri. | |
| WO2014108484A3 (en) | Combination therapy of anti-her3 and anti-her2 antibodies | |
| MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
| IN2014DN05885A (es) | ||
| MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| PH12016500753B1 (en) | Antibodies specific to fcrn | |
| MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
| MX2015013380A (es) | Inmunoterapia para cordoma a base de levadura. | |
| GR20140100616A (el) | Συστημα διαπροσωπικης επικοινωνιας δεδομενων και φωνης για οχηματα και μεθοδος χειρισμου | |
| PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
| TN2014000225A1 (en) | Methods of treatment using an antibody against interferon gamma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |